Navigation Links
AVAC Calls for AIDS Vaccine Field to Implement New Scientific Strategic Plan Released by Global HIV Vaccine Enterprise
Date:9/7/2010

NEW YORK, Sept. 7 /PRNewswire-USNewswire/ -- AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.

The Plan comes at a crucial time in the field. In the last year, the RV144 Thai vaccine trial proved that an AIDS vaccine is possible, which along with the identification of new potent, HIV-specific neutralizing antibodies, has re-energized AIDS vaccine researchers, advocates and funders.

"This is the most exciting period in HIV vaccine research in the last three decades. As we enter this new era in vaccine and HIV prevention research, scientists, funders and advocates are grappling with both the excitement of scientific breakthroughs and the realities of funding shortfalls. This plan has the potential to help meet the current challenges in the field," said Mitchell Warren, AVAC executive director. "But a plan is only as good as its execution, and AVAC will be watching and reporting on how the field comes together to capitalize both on the consensus of the plan and the promise of the science."

The new Scientific Strategic Plan provides important signposts for the way forward, but the field must also be willing to be flexible and adaptable to quickly react to the changing realities of the AIDS epidemic and biomedical research.

"This plan proposes a comprehensive strategy that goes beyond the scientific activities of any single funder or organization," said Bill Snow, a co-founder of AVAC, who was involved in the planning process. "There is now an urgent need to broaden international participation in the work that is necessary to build on the recent developments that have made HIV vaccine design and development as exciting and essential as it has ever been."

AVAC recommends the following actions to realize the potential of the Plan:

  • The Enterprise, through the secretariat and its governing Council, develop a comprehensive and ambitious resource mobilization strategy that identifies key gaps, new funding sources and opportunities to make the best use of already committed funds.
  • The Enterprise secretariat, with guidance and input from its scientific working groups, identify priority, time-sensitive issues that could be resolved or refined through immediate, Enterprise-led action.
  • Each Enterprise member articulate how their funding and/or scientific decisions are aligned with the Plan, or articulate why not.

AVAC believes it is crucial that the Global HIV Vaccine Enterprise Council, Director and Secretariat drive execution of the plan. Collectively, they should hold themselves and the full range of stakeholders, including donors, scientists and organizations, accountable for matching their work to the plan's priorities with urgency.

"Now more than ever, HIV vaccine research must also be seen in the context of the overall research agenda for HIV prevention," Warren added. "Even as this plan is executed, the AIDS vaccine field must adapt to emerging results from other biomedical prevention trials, such as microbicides and pre-exposure prophylaxis (PrEP), by preparing for positive data with new ideas for trial design and combination prevention."

AVAC's annual state of the field report on vaccines and HIV prevention research, which provides more information about the way forward for prevention research and more detail about out expectations of the Global HIV Vaccine Enterprise, is available online at www.avac.org/avacreport. The Global HIV Vaccine Enterprise Scientific Strategic Plan is being published open access today by Nature Medicine and available at www.vaccineenterprise.org.

About AVAC: Founded in 1995 as the AIDS Vaccine Advocacy Coalition, AVAC is an international, non-profit organization that uses education, policy analysis, advocacy and community mobilization to accelerate the ethical development and eventual global delivery of AIDS vaccines and other new HIV prevention options as part of a comprehensive response to the pandemic. Please visit www.avac.org.


'/>"/>
SOURCE AIDS Vaccine Advocacy Coalition
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DePuy Orthopaedics Voluntarily Recalls ASR™ Hip System
2. NORD Calls for Statement of Policy on Orphan Drug Development
3. Data Shows Ambulance Fees Will Deter Emergency Calls for Help
4. AdMeTech Calls for Major Research Commitment to End Prostate Cancer Crisis
5. P&G Voluntarily Recalls DayQuil Cold & Flu 24-Count LiquiCaps
6. Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping Unreasonable, Unfair and Discriminatory
7. Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels
8. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
9. Leading Trauma Surgeon Paints a Bleak Picture of U.S. Trauma System - Calls for Surgeons to Advocate for Systems Where Lacking
10. American Brain Tumor Association Calls for Discovery Research
11. GAA Calls on Secretary Clinton to Speak Out Against Gender-Based Violence During Her Africa Trip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices Market was ... 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular stent ... dominate the market during the study period. Continue Reading ... ... ...
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
Breaking Medicine Technology:
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
Breaking Medicine News(10 mins):